Portal de Periódicos da CAPES

Diabetes alters the protein secretome of human adipose‐derived stem cells and promotes tumorigenesis in hepatic cancer cells

2022; Springer Science+Business Media; Volume: 12; Issue: 6 Linguagem: Inglês

10.1002/ctm2.823

2001-1326

Miriam Ejarque, Joan Sabadell‐Basallote, Ester Benaiges, Catalina Núñez‐Roa, Eduard Sabidó, Eva Borràs, Erik Llàcer, António Zorzano, Joan Vendrell, Sonia Fernández‐Veledo,

Cancer, Hypoxia, and Metabolism

Metabolic dysfunction alters the properties of human adipose-derived stem cells (hASCs), which are central to adipose tissue (AT) homeostasis and might also influence tumour microenvironments.1 Therefore, new knowledge of the secretory capacity of hASCs would be important not only in terms of AT physiology, but might also provide insights into tumorigenesis. This is particularly relevant for diabetes, as several studies have demonstrated that patients with type 2 diabetes (T2D) are at increased risk of developing several different types of cancer.2, 3 In the present study, we assessed the protein secretome of hASCs in a background of T2D (independent of obesity) using an untargeted proteomic analysis, and its potential relevance for their pro-tumoral activity (Supporting Information). Our study reveals the importance of hASCs not only in metabolic disturbances, but also in tumorigenesis. The secretome profiling of hASCs isolated from the subcutaneous AT of subjects with and without T2D was performed. Characteristics of the donors are summarized in Table S1. We observed that the hASC secretomes from the two groups displayed a different profile with good protein coverage (Figure S1A,B). Notably, global protein secretion was higher in T2D-derived hASCs than in control hASCs (p < 0.039) (Figure S1A). Sample clustering and principal component analysis showed that one of the control samples grouped with the T2D samples and it was removed from the analysis (Figure S1C,D). The exploratory study was based on proteins detected in at least five of the six independent samples of the two groups, which was established to focus on traceable proteins. From this analysis, we observed a total of 231 unique proteins, of which 52 were identified to be differentially secreted (Figure 1A–C); 42 were secreted more by T2D-derived hASCs (81% of all differentially secreted proteins) and 10 were secreted less by T2D-derived hASCs (19%). The majority of secretory proteins are transported by the “conventional” secretion pathway to the plasma membrane, which involves the endoplasmic reticulum (ER) and the Golgi complex and is dependent on a signalling peptide; however, a significant number of proteins reach the plasma membrane/extracellular space via unconventional protein secretion (UPS) pathways independent of a signalling peptide.4 The 231 identified secreted proteins were examined for the presence of an N-terminal signalling peptide by in silico functional analysis,5 which revealed that only 46.7% of the proteins were predicted to be released through the conventional trafficking pathway. Of the 10 proteins secreted less by T2D-derived hASCs, 8 (80%) were predicted to be secreted by the conventional pathway. By contrast, only 19 of the 42 (45.2%) proteins secreted more by T2D-derived hASCs were predicted to be transported by the conventional pathway. This finding suggests that UPS pathways are triggered by pathological conditions. Functional analysis using STRING showed that differentially secreted proteins were associated with unique biological processes. Thus, network analysis of the proteins secreted more by T2D-derived hASCs revealed a significant protein–protein interaction (PPI) enrichment of the network (Figure 2A). We focused on the more enriched pathways, based on the obtained p-values in the curated databases, which included pathways associated with ER stress, extracellular matrix remodelling, cell adhesion and immune system, which are all directly related to cancer development and progression (Figure 2B).6 Network analysis of the proteins secreted less by T2D-derived hASCs indicated that these proteins were associated with wound healing and with a variety of protease inhibitor events (Figure 2C,D). Because AT (and by extension hASCs) play an important role in T2D and associated co-morbidities,7 the proteins secreted more by T2D-derived hASCs can be considered as potential candidates in the pathophysiology of these diseases. To validate these putative biomarkers, we focused on the top-15 over-secreted proteins by fold change (Figure 3A). We used COMPARTMENTS, a unification and visualization tool of protein subcellular localization to identify proteins with multiple locations on the cellular organization (Figure 3B). This tool also confirmed the secretable peptides identified previously by in silico analysis. Remarkably, our proteomic approach allowed us to identify specific secreted proteins that could act as common determinants of diabetes and cancer. We analysed the steady-state protein levels of CPPED1 (immune system pathway); fibroblast activation protein, FAP (movement, adhesion and projection); and hepatoma-derived growth factor, HDGF (ER stress and unfolded protein response) by western blotting. We also assessed the levels of activated RNA polymerase II transcriptional coactivator p15 (SUB1) and neudesin (NENF), which were not enriched in any of the main identified pathways, but are known to have an important role in tumorigenesis and metabolism.8, 9 Protein expression analysis validated three of the selected targets in whole hASCs extracts: FAP, NENF and SUB1 (Figure 3C). NENF has been previously described to be elevated in patients with T2D, and seems to be related to obesity and insulin resistance,10 so was not considered for further analysis. To test whether the diabetic secretome could modulate tumoral phenotypes we cultured human liver carcinoma (HepG2) cells for 24 h with CM from either T2D-derived hASCs or control-hASCs (Figure 4A), and we surveyed the expression of a panel of genes involved in inflammation, EMT, angiogenesis and invasiveness. We found that the expression of genes related to inflammation (TNFA), invasiveness (MMP2 and MMP9) and tumour growth and metastasis (VIM), was significantly higher in HepG2 cells cultured in the CM of T2D-hASCs than of control-hASCs (Figure 4A). We repeated the gene expression analysis in HepG2 cells using neutralizing antibodies to FAP or SUB1. Blocking SUB1 (Figure 4B) but not FAP (Figure S2 reverted the tumoral phenotype induced by T2D-hASC CM, as revealed by the significant downregulation of genes involved in inflammation (IL1B, TNFA), angiogenesis (VEGFA) and invasiveness (MMP9). Notably, neutralization of SUB1 also completely blocked the invasive properties of HepG2 cells in response to the T2D-hASC secretome (Figure 4C). Overall, these data establish the involvement of secreted factors derived from hASCs in a diabetes microenvironment in enhancing the malignancy of cancer cells, and how, specifically, SUB1 might promote cell switching to a tumoral phenotype. In conclusion, our study indicates that research into the systemic effects of the adipose-derived secretome may yield important insights into specific channels of systemic communication between the AT and tumours. We postulate that in a diabetic setting, hASCs acquire a pro-tumoral secretome, including an over-representation of SUB1, a secreted factor that can be internalized by surrounding cells to promote tumour progression. Further research will be needed to gain a better understanding of the molecular mechanisms underlying the interaction between components of the tumour microenvironment, and how such complex communication networks might be promoted in pathological environments such as those related to metabolic disorders. Finally, future preclinical studies should confirm that targeting SUB1 in vivo can modulate and prevent cancer progression. We want to particularly acknowledge the patients and the BioBank IISPV (PT17/0015/0029) integrated in the Spanish National Biobanks Network for its collaboration. We thank Dr. Kenneth McCreath for helpful comments on the manuscript and Dr. Alfonso Saera-Vila for his advice on bioinformatics. This study was supported by grants from Fundació la Marató de TV3 (PV170125) and from the Spanish Ministry of Economy and Competitiveness PI20/00338 and PI17/01503 to J.V., SAF2015-65019-R and RTI2018-093919 to S.F.-V., co-financed by the European Regional Development Fund (ERDF). The Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders (CIBERDEM) (CB07708/0012) is an initiative of the Instituto de Salud Carlos III. M.E. received a Generalitat de Catalunya grant for the incorporation of scientists PERIS (SLT002/16/00120). J.S.-B. is a recipient of a predoctoral contract for training in health research from the Insituto de Salud Carlos III, co-financed by the European Social Fund (PFIS FI18/00151). S.F.-V. acknowledges support from the “Miguel Servet” tenure track program CP10/00438 and CPII16/0008 from the Fondo de Investigación Sanitaria, co-financed by the ERDF. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is member of ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I+D+i 2013-2016 from the Instituto de Salud Carlos III (ISCIII), ERDF, and “Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). We also acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya. The authors declare no conflict of interest. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.